

16. (Amended) The cross-over protein of claim 14, wherein said functional protein module comprises [an] a C-terminal module corresponding to a SEQ ID NO selected from the group consisting of SEQ ID NO: [17-20] 19-22.

don't 17. (Amended) The cross-over protein of claim 14, wherein said cross-over chemokine corresponds to a SEQ ID NO selected from the group consisting of SEQ ID NO: [3, 4, 22-24, 26-39, 41-43] 5, 6, 24-26, 28-41, 43-45 and [45-52] 47-54.

23. (Amended) The protein library of claim 22, wherein said functional protein module comprises [an] a N-terminal module corresponding to a SEQ ID NO selected from the group consisting of SEQ ID NO: [9-16] 11-18.

a² 24. (Amended) The protein library of claim 22, wherein said functional protein module comprises [an] a C-terminal module corresponding to a SEQ ID NO selected from the group consisting of SEQ ID NO: [17-20] 19-22.

25. (Amended) The protein library of claim 22, wherein one or more of said cross-over chemokines correspond to a SEQ ID NO selected from the group consisting of SEQ ID NO: [3, 4, 22-24, 26-39, 41-43] 5, 6, 24-26, 28-41, 43-45 and [45-52] 47-54.

a³ 27. (Amended) A kit comprising a cross-over protein according to [any one of claims 1-26] claim 1.

49. (Amended) The method of claim 48, wherein said functional protein module comprises [an] a N-terminal module corresponding to a SEQ ID NO selected from the group consisting of SEQ ID NO: [9-16] 11-18.

a⁴ 50. (Amended) The method of claim 48, wherein said functional protein module comprises [an] a C-terminal module corresponding to a SEQ ID NO selected from the group consisting of SEQ ID NO: [17-20] 19-22.

51. (Amended) The method of claim 48, wherein said cross-over chemokine corresponds to a SEQ ID NO selected from the group consisting of SEQ ID NO: [3, 4, 22-24, 26-39, 41-43] 5, 6, 24-26, 28-41, 43-45 and [45-52] 47-54.